logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (3)
  • CSV
  • BibTeX
  • EndNote
  • All Results (3)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART

Van Heerden JK, Zhao Y, Keene CM, Griesel R, Omar Z,  et al.
2025-04-30 • South African Journal of HIV Medicine
2025-04-30 • South African Journal of HIV Medicine

BACKGROUND

Dol...

Journal Article
|
Research

Relationship between tenofovir diphosphate concentrations in dried blood spots and virological outcomes after initiating tenofovir-lamivudine-dolutegravir as first-line or second-line antiretroviral therapy

van Heerden JK, Meintjes G, Barr D, Zhao Y, Griesel R,  et al.
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
BACKGROUND
Tenofovir diphosphate (TFV-DP) concentration in dried blood spots is a marker of long-term adherence. We investigated the relationship between TFV-DP concentrations and vi...
Journal Article
|
Research

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L,  et al.
2023-05-22 • Lancet HIV
2023-05-22 • Lancet HIV
BACKGROUND
The drug-drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings....